Table 2.
CtIP/RBBP8 expression in breast cancer and its relationship with clinicopathological variables
| Absence | Low | Normal | P-value | |
|---|---|---|---|---|
| Tumor | ||||
| T1 | 46 (33.3) | 51 (45.5) | 36 (50.0) | 0.032 |
| T2 | 71 (51.4) | 43 (38.4) | 34 (47.2) | |
| T3 | 16 (11.6) | 13 (11.6) | 1 (1.4) | |
| T4 | 5 (3.6) | 5 (4.5) | 1 (1.4) | |
| Node | ||||
| Negative | 69 (47.9) | 52 (47.3) | 44 (64.7) | 0.044 |
| Positive | 75 (52.1) | 58 (52.7) | 24 (35.3) | |
| Grade | ||||
| 1 | 9 (5.8) | 15 (12.2) | 17 (20.7) | <0.0001 |
| 2 | 53 (34.4) | 42 (34.1) | 45 (54.9) | |
| 3 | 92 (59.7) | 66 (53.7) | 20 (24.4) | |
| ER | ||||
| Negative | 64 (41.8) | 20 (16.3) | 7 (8.5) | <0.0001 |
| Positive | 89 (58.2) | 103 (83.7) | 75 (91.5) | |
| PR | ||||
| Negative | 75 (49.3) | 42 (33.9) | 18 (22) | 0.0001 |
| Positive | 77 (50.7) | 82 (66.1) | 64 (78) | |
| HER2 | ||||
| Negative | 123 (77.8) | 102 (81) | 75 (92.6) | 0.017 |
| Positive | 35 (22.2) | 24 (19) | 6 (7.4) | |
| Ki67 | ||||
| Negative | 23 (16.1) | 31 (29.0) | 23 (32.9) | 0.009 |
| Positive | 120 (83.9) | 76 (71) | 47 (67.1) | |
| Phenotype | ||||
| Luminal A | 22 (15.7) | 27 (23.9) | 21 (30) | <0.0001 |
| Luminal B HER2− | 53 (37.9) | 51 (45.1) | 41 (58.6) | |
| Luminal B HER2+ | 7 (5) | 15 (13.3) | 1 (1.4) | |
| HER2+ | 22 (15.7) | 6 (5.3) | 5 (7.1) | |
| Triple negative | 36 (25.7) | 14 (12.4) | 2 (2.9) | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2. Absolute number of biopsies assigned to each clinicopathological subtype and CtIP/RBBP8 expression level. The number in brackets represents the percentage of samples within a given category of CtIP/RBBP8 expression.